Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.25 USD | -1.32% | -18.79% | +57.59% |
05-10 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
05-09 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.59% | 1.63B | |
+29.52% | 48.16B | |
-1.11% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.12% | 25.59B | |
-22.92% | 18.96B | |
+8.17% | 12.92B | |
+29.18% | 12.03B | |
-1.80% | 11.77B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk